Cargando…
Off-Label Use of Botulinum Toxin in Dermatology—Current State of the Art
Botulinum toxin (BoNT) is a neurotoxin produced by the Clostridium botulinum bacteria. Among seven different isoforms, only BoNT-A and BoNT-B are commercially used. Currently, botulinum toxin has been indicated by the U.S. Food and Drug Administration in several disorders, among others: chronic migr...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9147387/ https://www.ncbi.nlm.nih.gov/pubmed/35630620 http://dx.doi.org/10.3390/molecules27103143 |
_version_ | 1784716795136966656 |
---|---|
author | Lewandowski, Miłosz Świerczewska, Zuzanna Barańska-Rybak, Wioletta |
author_facet | Lewandowski, Miłosz Świerczewska, Zuzanna Barańska-Rybak, Wioletta |
author_sort | Lewandowski, Miłosz |
collection | PubMed |
description | Botulinum toxin (BoNT) is a neurotoxin produced by the Clostridium botulinum bacteria. Among seven different isoforms, only BoNT-A and BoNT-B are commercially used. Currently, botulinum toxin has been indicated by the U.S. Food and Drug Administration in several disorders, among others: chronic migraine, hyperhidrosis, urinary incontinence from detrusor overactivity, or cosmetics. However, there are numerous promising reports based on off-label BTX usage, indicating its potential effectiveness in other diseases, which remains unknown to many. Among them, dermatological conditions, such as rosacea, annal fissure, Raynaud phenomenon, hypertrophic scars and keloids, and also hidradenitis suppurativa, are currently being investigated. This article aims to provide a comprehensive update on the off-label use of botulinum toxin in dermatology, based on an analysis and summary of the published literature. |
format | Online Article Text |
id | pubmed-9147387 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91473872022-05-29 Off-Label Use of Botulinum Toxin in Dermatology—Current State of the Art Lewandowski, Miłosz Świerczewska, Zuzanna Barańska-Rybak, Wioletta Molecules Review Botulinum toxin (BoNT) is a neurotoxin produced by the Clostridium botulinum bacteria. Among seven different isoforms, only BoNT-A and BoNT-B are commercially used. Currently, botulinum toxin has been indicated by the U.S. Food and Drug Administration in several disorders, among others: chronic migraine, hyperhidrosis, urinary incontinence from detrusor overactivity, or cosmetics. However, there are numerous promising reports based on off-label BTX usage, indicating its potential effectiveness in other diseases, which remains unknown to many. Among them, dermatological conditions, such as rosacea, annal fissure, Raynaud phenomenon, hypertrophic scars and keloids, and also hidradenitis suppurativa, are currently being investigated. This article aims to provide a comprehensive update on the off-label use of botulinum toxin in dermatology, based on an analysis and summary of the published literature. MDPI 2022-05-13 /pmc/articles/PMC9147387/ /pubmed/35630620 http://dx.doi.org/10.3390/molecules27103143 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Lewandowski, Miłosz Świerczewska, Zuzanna Barańska-Rybak, Wioletta Off-Label Use of Botulinum Toxin in Dermatology—Current State of the Art |
title | Off-Label Use of Botulinum Toxin in Dermatology—Current State of the Art |
title_full | Off-Label Use of Botulinum Toxin in Dermatology—Current State of the Art |
title_fullStr | Off-Label Use of Botulinum Toxin in Dermatology—Current State of the Art |
title_full_unstemmed | Off-Label Use of Botulinum Toxin in Dermatology—Current State of the Art |
title_short | Off-Label Use of Botulinum Toxin in Dermatology—Current State of the Art |
title_sort | off-label use of botulinum toxin in dermatology—current state of the art |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9147387/ https://www.ncbi.nlm.nih.gov/pubmed/35630620 http://dx.doi.org/10.3390/molecules27103143 |
work_keys_str_mv | AT lewandowskimiłosz offlabeluseofbotulinumtoxinindermatologycurrentstateoftheart AT swierczewskazuzanna offlabeluseofbotulinumtoxinindermatologycurrentstateoftheart AT baranskarybakwioletta offlabeluseofbotulinumtoxinindermatologycurrentstateoftheart |